| Contact Information: |
|
Phone: (603) 653-6181
|
|
Fax: (603) 653-6191
|
| Email: not given |
|
| Institution Affiliations: |
| Associate Professor of Medicine (Hematology/Oncology) |
| Department of: MEDICINE |
| Section: Hematology/Oncology |
| Specialty: Breast Cancer |
| Joined Staff: 1992 |
| Cancer Center Membership: |
| Clinical Interests: |
| Breast Cancer |
|
| Board Certified: |
| Hematology 1990 |
| Medical Oncology 1989 |
| Internal Medicine 1986 |
|
| New York University School of Medicine, New York, NY 1983 |
| Duke University Medical Center, Durham, NC, (Internal Medicine) 1983-86 |
| Duke University Medical Center, Durham, NC, (Hematology) , and Medical Oncology
1986-89 |
| Dr. Kaufman received his BA from Bowdoin College and his MD from New York University School of Medicine. He completed his residency in internal medicine and a fellowship in Hematology and Oncology at Duke University Medical Center. In 1989 he joined the faculty of Duke and then came to the Dartmouth Hitchcock Medical Center in January 1992 as a breast cancer specialist. |
| Dr. Kaufman's research interests include various aspects of breast cancer, and newer therapeutic strategies in treating breast cancer. These include HER-2 targeted therapies, and testing of HER-2. Additionally, his other interests include the study of other novel biologic agents in breast cancer, as well as novel chemotherapeutic agents. |
| A recent article in Internal Medicine News (September, 2007) focuses on Dr. Kaufman's research on polysomy and the HER2 gene. |
Kaufman PA. Paclitaxel and Anthracycline Combination Chemotherapy For Metastatic Breast Cancer. Seminars in Oncology, 26 (3 Suppl 8): 39-46, 1999.
Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, and Perez EA. Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831. Journal of the National Cancer Institute, 94: 855-857, 2002.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CEJ, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine 353: 1673-84, 2005.
Kaufman PA. HER-2/neu The Role of Trastuzumab (Herceptin®) in Early Stage Breast Cancer: Highlights of Recent Findings. E-Updates Quarterly Monographs: HER-1 and HER-2 Targeting in Cancer, 12/05: 1-9. Ellis, MJ, Editor. CancerNetwork.Com, CMP Publishing.
Bubis JA, Weaver D, Wells WA, Cole BF, Cates J, Schwartz G, Muss HB, Kaufman PA. HER-2/neu Overexpression: Immunohistochemistry (IHC) or Fluorescence In-Situ Hybridization (FISH)? Breast Cancer Research & Treatment, 82: 602A, 2003.
Kaufman PA, Paroly W, Rinaldi D, Sonnier S, Shahin S, Dean L, Dansey R, Burris S. Randomized double-blind phase 2 study evaluating same-day vs next-day administration of pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with early stage and advanced breast cancer. Breast Cancer Research and Treatment, 88, A1054, 2004
Kaufman PA, Schwartz GN, Bubis JA, Cates J, Wells WA, Moore CP, Connelly EM, Muss HB, Weaver DL. Aneusomy of chromosome (chrom) 17: an alternative mechanism of low level HER-2/new gene amplification that correlates with immunohistochemical (IHC) 2+ protein expression. Breast Cancer Research and Treatment, 88, A1036, 2004
Schwartz GN, Kaufman PA, Tretter CPG, Arrick BA, Mulrooney TJ, Connelly EM, Mellinger DL, Fisher JL, Ernstoff MS. Vinorelbine and trastuzumab enhance effector cell function in patients with HER-2/neu overexpressing metastatic breast cancer. Breast Cancer Research and Treatment, 88, A3048, 2004
Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P, on Behalf of NCCTG, ECOG, SWOG, CALGB. NCCTG 9831: May 2005Update. Advances in Monoclonal Antibody Therapy for Breast Cancer, ASCO Scientific Symposium. Proc ASCO, 23, 2005
Romond EH, Perez EA, Bryant J, Suman V, Geyer CE, Davidson N, Tan-Chiu E, Martino S, Swain SM, Kaufman P, Fehrenbacher L, Pisansky T, Vogel V, Kutteh LA, Yothers G, Visscher D, Brown AM, Jenkins R, Seay TE, Mamounas E, Abrams J, Wolmark N. Doxorubicin and Cyclophosphamide Followed by Paclitaxel with or without Trastuzumab as Adjuvant Therapy for Patients with HER-2 Positive Operable Breast Cancer. Advances in Monoclonal Antibody Therapy for Breast Cancer, ASCO Scientific Symposium. Proc ASCO, 23, 2005
Kaufman PA, Mayer M, Paik S, Ulcickas-Yood M, Yardley D, Tan-Chiu E, Brufsky A, Rugo H, Tripathy D, Thomas E, Dolezal M, Wang L, Brammer M. registHER: Trastuzumab-based taxane or vinorelbine treatment selection in patients with HER-2/neu (+) metastatic breast cancer: patient characteristics and preliminary outcomes. Breast Cancer Research and Treatment, 95, A2066, 2006. |
|
|
|
|
Mailing Address:
Norris Cotton Cancer Center
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, NH 03756
|
|
